Advancing clinical trials to streamline drug development

Clinical Cancer Research

Volumn 21, Issue 20, 2015, Pages 4527-4535

  Bates, Susan E ^a   Berry, Donald A ^b   Balasubramaniam, Sanjeeve ^c   Bailey, Stuart ^d   LoRusso, Patricia M ^e   Rubin, Eric H ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e YALE CANCER CENTER   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER DIAGNOSIS; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); DOSE CALCULATION; DRUG APPROVAL; DRUG CONTROL; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENE SEQUENCE; GENETIC HETEROGENEITY; HEALTH CARE DELIVERY; HUMAN; IMMUNE SYSTEM; INFORMATION PROCESSING; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; ANIMAL; DRUG DEVELOPMENT; GENETICS; GENOMICS; NEOPLASMS; PERSONNEL; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; GENOMICS; HUMANS; NEOPLASMS; RESEARCH PERSONNEL;

EID: 84945535777     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0039     Document Type: Article

References (46)

1. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-65.
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298:1912-34.
3. Poole RM. Pembrolizumab: first global approval. Drugs 2014;74:1973-81.
4. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16: 375-84.
5. Berry DA. The Brave New World of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol 2015;9:951-9.
6. Siu LL, Conley BA, Boerner S, LoRusso PM. Next-generation sequencing to guide clinical trials. Clin Cancer Res 2015;21:4536-44.
7. Eastman P. Janet Woodcock: FDA will soon issue guidance on co-development of drugs and diagnostics. Oncol Times 2013;35:11-2.
8. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. ISPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
9. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2012;9:199-207.
10. Berry DA, Herbst RS, Rubin EH. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clin Cancer Res 2012;18:638-44.
11. Guidance for industry: pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an end point to support accelerated approval [PDF on the Internet]. Silver Spring, MD: U.S. Food and Drug Administration; 2014 [cited 2015 Jul 25]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf.
12. RugoHS, Olopade O, DeMichele A, van't Veer L, BuxtonM,HyltonN, et al. Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 TRIAL. Cancer Res 2013;73(24 Suppl). Abstract nr S5-02.
13. Park JW, Liu MC, Yee D, DeMichele A, van't Veer L, Hylton N, et al. Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: efficacy results from the I-SPY 2 TRIAL [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl). Abstract nr CT227.
14. Tripathy D, Chien AJ, Hylton N, Buxton MB, Ewing CA, Wallace AM, et al. Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: graduation results from the I-SPY 2 Trial. J Clin Oncol 33, 2015 (suppl; abstr 524).
15. FDA approves Perjeta for neoadjuvant breast cancer treatment. FDA News Release; 2013 Sep 30 [cited 2015 Jul 25]. Available from: http://www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm370393.htm.
16. Amiri-Kordestani L, Wedam S, Zhang L, Tang S, Tilley A, Ibrahim A, et al. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res 2014;20:5359-64.
17. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, LiuMC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32.
18. Scher HI, Nasso SF, Rubin EH, Simon R. Adaptive clinical trial designs for simultaneous testing ofmatched diagnostics and therapeutics. Clin Cancer Res 2011;17:6634-40.
19. Storer BE. A sequential phase II/III trial for binary outcomes. Stat Med 1990;9:229-35.
20. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990;46: 33-48.
21. Faries D. Practical modifications of the continual reassessmentmethod for phase I cancer clinical trials. J Biopharm Stat 1994;4:147-64.
22. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM. A comparison of two phase I trial designs. Stat Med 1994;13:1799-806.
23. Moller S. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Stat Med 1995;14:911-22; discussion 923.
24. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 1998;17:1103-20.
25. FDA'sCritical Path Initiative [about 2 screens] [cited 2015 Jul 25]. Available from: http://www.fda.gov/scienceresearch/specialtopics/criticalpathinitiative/ucm076689.htm#.
26. Cosmatos D, Chang-Chow S, editors. Translational medicine: strategies and statistical methods. Boca Raton, FL: Chapman and Hall; 2009.
27. Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A. Translation of innovative designs into phase I trials. J Clin Oncol 2007; 25:4982-6.
28. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708-20.
29. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 2008;27:2420-39.
30. Bailey S, Neuenschwander B. Bayesian model-based approaches for single and combination dose finding [PDF on the Internet]. Alexandria (VA): American Statistical Association; 2011 [cited 2015 Jul 25]. Available from: http://www.amstat.org/sections/sbiop/webinars/2011/Presentation4-27-2011.pdf.
31. Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, et al. First-inhuman phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res 2013;19:3671-80.
32. Dose-Finding of Small Molecule Oncology Drugs [about 13 screens] [cited 2015 Jul 25]. Available from: http://www.aacr.org/AdvocacyPolicy/GovernmentAffairs/Pages/dose-finding-of-small-molecule-oncology-drugs. aspx.
33. Neuenschwander B, Matano A, Tang Z, Roychoudhury S, Wandel S, Bailey S. A Bayesian industry approach to phase I combination trials in oncology. In:Zhao W, Yang H, editors. Statistical methods in drug combination studies. Boca Raton, FL: CRC Press; 2015.
34. Theoret MR, Pai-Scherf LH, Chuk MK, Prowell TM, Balasubramaniam S, Kim T, et al. Expansion cohorts in first-in-human solid tumor oncology trials. Clin Cancer Res 2015;21:4545-51.
35. Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, et al. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res 2013;19:2289-93.
36. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364:205-14.
37. O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, NeubauerM, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triplenegative breast cancer. J Clin Oncol 2014;32:3840-7.
38. Seruga B, Ocana A, Amir E, Tannock IF. Failures in phase III: causes and consequences. Clin Cancer Res 2015;21:4552-60.
39. Bellary S, Krishnankutty B, Latha MS. Basics of case report form designing in clinical research. Perspect Clin Res 2014;5:159-66.
40. StewartDJ, Batist G, KantarjianHM, Bradford J-P, Schiller JH,Kurzrock R. The urgent need for clinical research reform to permit faster, less expensive access to new therapies for lethal diseases. Clin Cancer Res 2015;21:4561-68.
41. Fouad MN, Lee JY, Catalano PJ, Vogt TM, Zafar SY, West DW, et al. Enrollment of patients with lung and colorectal cancers onto clinical trials. J Oncol Pract 2013;9:e40-7.
42. Gerber DE, Lakoduk AM, Priddy LL, Yan J, Xie XJ. Temporal trends and predictors for cancer clinical trial availability for medically underserved populations. Oncologist 2015;20:674-82.
43. Schroen AT, Petroni GR, Wang H, Gray R, Wang XF, Cronin W, et al. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials 2010;7:312-21.
44. Carlisle B, Kimmelman J, Ramsay T, MacKinnon N. Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials. Clin Trials 2015;12:77-83.
45. Patient Protection and Affordable Care Act of 2010, Pub. L. No. 2709, 117 Stat. 2272 (Dec 24, 2009). Available from: http://www.hhs.gov/healthcare/rights/law/patient-protection.pdf.
46. Guidance for industry: adaptive design clinical trials for drugs and biologics [PDF on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2010 [cited 2015 Jul 25]. Available from: http://www.fda. gov/downloads/Drugs/Guidances/ucm201790.pdf.